191 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Clinical Pharmacology Audio PeerVoice

    • Science
    • 5.0 • 3 Ratings

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights From the 2021 Virtual ERA-EDTA Congress

    Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights From the 2021 Virtual ERA-EDTA Congress

    Visit https://www.peervoice.com/BFW860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights From the 2021 Virtual ERA-EDTA Congress”, participants will be able to: Describe key safety and efficacy data on SGLT2 inhibition for the management of chronic kidney disease (CKD); Summarise what the latest data on SGLT2 inhibition add to the current treatment algorithm for CKD; Discuss the clinical implications of SGLT2 inhibition in the context of managing patients with CKD.

    • 8 min
    Identifying Bowel Urgency in Patients With Ulcerative Colitis: The Need for Speed

    Identifying Bowel Urgency in Patients With Ulcerative Colitis: The Need for Speed

    Visit https://www.peervoice.com/WHZ860 to view the entire programme with slides. After completing “Identifying Bowel Urgency in Patients With Ulcerative Colitis: The Need for Speed”, participants will be able to: Explain how bowel urgency can impact a patient’s quality of life; Apply practical strategies for identifying and assessing patients with ulcerative colitis who are suffering from bowel urgency; Describe the clinical data for emerging therapies that are being assessed on their impact on bowel urgency.

    • 59 min
    Suspecting, Diagnosing and Managing Multifocal Motor Neuropathy: A Patient Investigation

    Suspecting, Diagnosing and Managing Multifocal Motor Neuropathy: A Patient Investigation

    Visit https://www.peervoice.com/YGF860 to view the entire programme with slides. After completing “Suspecting, Diagnosing and Managing Multifocal Motor Neuropathy: A Patient Investigation”, participants will be able to: Recognise the patient characteristics and clinical features that would raise a high index of suspicion of multifocal motor neuropathy (MMN) and a need for referral for diagnostic tests; Describe the current thinking on the pathological processes at play in MMN and the rationale for why immunoglobulin (Ig) therapy is effective; Identify available and recent developments in Ig therapy and the potential impact on patient outcomes.

    • 49 min
    Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?

    Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?

    Visit https://www.peervoice.com/RJT860 to view the entire programme with slides. After completing “Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?”, participants will be able to: Explain the unmet medical needs in diffuse large B-cell lymphoma (DLBCL); Assess the latest clinical data for novel and emerging antibody strategies for the treatment of relapsed/refractory DLBCL; Translate available clinical data for immunotherapeutic strategies into practical guidance for the clinic in order to maximise patient outcomes.

    • 58 min
    Going the Distance in HIV: Simplifying ART at Every Stage

    Going the Distance in HIV: Simplifying ART at Every Stage

    Visit https://www.peervoice.com/GFQ860 to view the entire programme with slides. After completing “Going the Distance in HIV: Simplifying ART at Every Stage”, participants will be able to: Explain the rationale for assessing and addressing the need for simplification of ART; Evaluate clinical implications of recent data on simplified ART in a variety of patient scenarios; Develop simplified ART based on individual patient- and disease-related factors.

    • 24 min
    Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?

    Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?

    Visit https://www.peervoice.com/QZT860 to view the entire programme with slides. After completing “Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?”, participants will be able to: Discuss the rationale for checkpoint inhibitors in the management of advanced or recurrent endometrial cancer; Evaluate recent data for current and emerging checkpoint inhibitors for the management of advanced or recurrent endometrial cancer; Identify common and serious adverse events associated with checkpoint inhibitors and their management in advanced or recurrent endometrial cancer.

    • 26 min

Customer Reviews

5.0 out of 5
3 Ratings

3 Ratings

Top Podcasts In Science

Listeners Also Subscribed To